TSX drops after Canadian index edges higher in prior session
Investing.com - Leerink Partners raised its price target on BridgeBio Pharma (NASDAQ:BBIO) to $75.00 from $68.00 while maintaining an Outperform rating following the company’s third-quarter financial results. The new target represents potential upside from the current price of $66.62, with the stock trading near its 52-week high of $69.48. According to InvestingPro data, BBIO has delivered an impressive 142.78% return year-to-date.
BridgeBio reported U.S. Attruby sales of $108 million, slightly ahead of Leerink’s estimate of $105 million and consensus of $102 million. As of October 25, 2025, the company recorded 5,259 unique prescriptions from 1,355 unique prescribers, representing approximately 115 incremental scripts per week. This performance contributes to the company’s last twelve months revenue of $235.81 million, with InvestingPro data showing revenue growth of 7.62%. Despite this growth, BridgeBio is not yet profitable, with analysts not expecting profitability this year.
The company noted strong double-digit month-over-month growth in treatment-naïve patients, estimating new patient share well into the 20% range, up from approximately 18-20% in the second quarter. Outside the U.S., where BridgeBio partners with Bayer and Alexion (AstraZeneca), the company recorded $4.3 million in royalties.
In Germany, BridgeBio’s Beyonttra captured 47% of new prescription share, signaling strong potential for future European launches. Management expects the U.S./EU sales ratio to be similar to Pfizer’s tafamidis.
BridgeBio recently reported positive topline results for BBP-418 (for LGMD2I/R9) and encaleret (for ADH1), diversifying beyond TTR amyloidosis and setting the stage for two additional rare disease launches in the next 12-18 months, with NDA submissions expected in the first half of 2026. With a market capitalization of $12.74 billion and analyst consensus strongly bullish at 1.37, BridgeBio’s pipeline progress continues to drive investor interest. For deeper insights into BBIO’s financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, BridgeBio Pharma Inc. reported its third-quarter 2025 earnings, showing a larger-than-expected loss but outperforming revenue predictions. The company posted an earnings per share (EPS) of -$0.95, which was below the forecasted -$0.88. However, BridgeBio Pharma’s revenue reached $120.7 million, surpassing the anticipated $107.62 million. These financial results reflect the company’s ability to exceed revenue expectations despite the earnings shortfall. The announcement of these results was followed by a rise in BridgeBio’s stock during trading hours. This development highlights the market’s positive reaction to the revenue beat. Investors will be closely monitoring any future updates from BridgeBio Pharma as these recent developments unfold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.